Treatment Strategy for Cancer-associated Venous Thromboembolism During Chemotherapy: The Keep ACT2 Concept

• Published in: Cancer diagnosis & prognosis 2021-11, Vol.1 (5), p.417-422
• Main Authors: Tanaka, Yoshihiro, Sato, Yuta, Suetsugu, Tomonari, Mase, Junichi, Takaha, Ritsuki, Okumura, Naoki, Matsuhashi, Nobuhisa, Takahashi, Takao, Yoshida, Kazuhiro
• Format: Article
• Language: English
• ISSN: 2732-7787; 2732-7787
• DOI: 10.21873/cdp.10055

The frequency of detecting cancer-associated venous thromboembolism (CAT) during chemotherapy is increasing. It is not desirable to discontinue chemotherapy for CAT. In this study, we investigated the feasibility of simultaneous progression of anticoagulant and anticancer therapy, focusing on drug interactions. We retrospectively evaluated patients with gastroenterological CAT from February 2017 to December 2020 at the Gifu University Hospital. When both chemotherapy and CAT treatments using edoxaban were performed in parallel and the thrombus disappeared, patients were defined as being Keep-ACT (keeping anticancer therapy and anticoagulant therapy) successful. The effect and safety of treatment strategy focusing on cytochrome P450 (CYP) metabolism using edoxaban were evaluated. A total of 114 patients with CAT during chemotherapy were treated with edoxaban. Keep-ACT was successful in 101 (88.6%) cases. Clinically relevant non-major bleeding was observed in 5 cases (4.4%). All 114 patients were using some drug affected by CYP metabolism, and the median number of affected cases was 5. Combined use of edoxaban for CAT may lead to sustainable therapy for gastroenterological cancer patients who are administered several drugs.